Results 121 to 130 of about 2,108,740 (316)

Interleukin‐33‐nuclear factor‐κB‐CCL2 signaling pathway promotes progression of esophageal squamous cell carcinoma by directing regulatory T cells

Cancer Science, 2019
Esophageal cancer is currently one of the most fatal cancers. However, there is no effective treatment. Increasing evidence suggests that interleukin (IL)‐33 has a significant role in tumor progression and metastasis.
Ying Yue, Jingyao Lian, Tianhong Wang, Chen Luo, Yi-Qiang Yuan, Guohui Qin, Bin Zhang, Yi Zhang   +7 more
semanticscholar   +1 more source

Group 2 Innate Lymphoid Cells Are Redundant in Experimental Renal Ischemia-Reperfusion Injury. [PDF]

, 2019
Acute kidney injury (AKI) can be fatal and is a well-defined risk factor for the development of chronic kidney disease. Group 2 innate lymphoid cells (ILC2s) are innate producers of type-2 cytokines and are critical regulators of homeostasis in ...
Cameron, Guy JM, Cautivo, Kelly M, Deshpande, Aniruddh V, Foster, Paul S, Hansbro, Philip M, Jiang, Simon H, Loering, Svenja, McKenzie, Andrew NJ, Molofsky, Ari B, Starkey, Malcolm R   +9 more
core   +4 more sources

The enigmatic processing and secretion of interleukin-33 [PDF]

Cellular & Molecular Immunology, 2010
Interleukin-33 (IL-33) is the most attractive novel cytokine identified as an IL-1 family member. IL-33 was first named NF-HEV (nuclear factor from high endothelial venules), as it was known to interact with nuclear chromatin although its exact intracellular functions are still to be clarified.
Weihua, Zhao, Zhiqing, Hu
openaire   +2 more sources

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Arthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Y. Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

IL (Interleukin)-33 Suppresses Abdominal Aortic Aneurysm by Enhancing Regulatory T-Cell Expansion and Activity

Arteriosclerosis, Thrombosis and Vascular Biology, 2019
Objective— Inflammation occurs during the progression of abdominal aortic aneurysm (AAA). IL (interleukin)-33 is a pleiotropic cytokine with multiple immunomodulatory effects, yet its role in AAA remains unknown.
Jingyong Li, Ni Xia, Shuang Wen, Dan Li, Yuzhi Lu, Muyang Gu, T. Tang, Jiao Jiao, Bing-Jie Lv, Shaofang Nie, Meng-yang Liao, Yuhua Liao, Xiangping Yang, Yu Hu, G. Shi, Xiang Cheng   +15 more
semanticscholar   +1 more source

Comparison between soluble ST2 and high-sensitivity troponin I in predicting short-term mortality for patients presenting to the Emergency Department with chest pain [PDF]

, 2016
Background: High-sensitivity cardiac troponin I (hs-cTnI) and the soluble isoform of suppression of tumorigenicity 2 (sST2) are useful prognostic biomarkers in acute coronary syndrome (ACS).
Francesca Orsini, Gerardo Salerno, Laura Magrini, Mina Hur, null null, Patrizia Cardelli, Rossella Marino, Salvatore Di Somma, Veronica Russo   +8 more
core   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Sex Differences in Medication Discontinuation in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Interleukin‑33 promotes obstructive renal injury via macrophages

Molecular Medicine Reports, 2019
Chronic kidney disease is the outcome of most kidney diseases, and renal fibrosis is a pathological process involved in the progression of these disorders. The role of interleukin (IL)‑33 was previously investigated in fibrotic disorders affecting various organs, including liver, lungs and heart; however, its role in renal fibrosis remains unclear ...
Yanlei, Li, Jing, Liu, Ting, Yu, Bingdi, Yan, Hongjun, Li   +4 more
openaire   +3 more sources

Diagnostic Use of Testing for Novel Murine Autoantibodies for Sjögren Disease in the Rheumatology Outpatient Setting

Arthritis Care &Research, EarlyView.
Objective The goal was to assess the diagnostic performance of three novel autoantibodies (NA) for Sjögren disease (SjD) by comparing NA prevalence in patients with SjD, other autoimmune rheumatic diseases (ARDs), nonspecific chronic sialadenitis (CS), and controls.
Chadwick R. Johr, Michael D. George, Vatinee Y. Bunya, Nora Sandorfi, Mina Massaro‐Giordano, Frederick B. Vivino   +5 more
wiley   +1 more source